AstraZeneca COVID-19 vaccine safety data - adolescent participants

Australia’s active vaccine safety system

AstraZeneca COVID-19 vaccine

Data on this page show the responses of adolescent participants aged less than 20 years who received the AstraZeneca COVID-19 vaccine and completed an AusVaxSafety survey sent on day 3 after vaccination. These data provide you with a profile of what to expect in the days following your AstraZeneca COVID-19 vaccination and can assist when planning for your COVID-19 vaccination. Please note, the AstraZeneca COVID-19 vaccine is only approved for those aged 18 years and older in Australia.

The profile of reported events from AusVaxSafety surveillance of the AstraZeneca COVID-19 vaccine is similar to that reported in clinical trials and from post-marketing surveillance overseas.

There have been no reports of thrombosis thrombocytopenia syndrome (TTS) following COVID-19 vaccination reported to AusVaxSafety. For more information on all vaccine safety monitoring in Australia and on TTS, see weekly TGA safety updates.

AusVaxSafety's active vaccine safety surveillance system complements the TGA's enhanced safety surveillance activities. Find out more about how the TGA monitors the safety of COVID-19 vaccines and how you can report side effects on the TGA website.

Links to further information on the expected profile for the AstraZeneca COVID-19 vaccine are available below:

AusVaxSafety will continue to closely monitor the safety data of all COVID-19 vaccines in use in Australia in conjunction with the TGA.

Last updated August 2022

AstraZeneca COVID-19 vaccine

Shingrix® vaccine safety data now available

AusVaxSafety receives funding
from the Australian Government

NCIRS, Kids Research, Sydney Children’s Hospitals Network, Cnr Hawkesbury Rd & Hainsworth St, Westmead Locked Bag 4001, Westmead NSW 2145 Tel (612) 9845 1433 | Fax (612) 9845 1418 | ABN 53 188 579 090

We acknowledge that the National Centre for Immunisation Research and Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.

Our website meets the criteria for credibility and content as defined by the Global Advisory Committee on Vaccine Safety.

We acknowledge that the National Centre for Immunisation Research & Surveillance (NCIRS) is on the land of the traditional owners the Aboriginal and Torres Strait Islander peoples, the First Australians, and recognise their culture, history, diversity and their deep connection to the land. Together, through research and partnership, we aim to move to a place of equity for all. NCIRS also acknowledges and pays respect to other Aboriginal and Torres Strait Islander nations from which our research, staff and community are drawn.

AstraZeneca COVID-19 vaccine safety data - adolescent participants

AstraZeneca COVID-19 vaccine

AstraZeneca COVID-19 vaccine

News & events

AusVaxSafety commences routine surveillance of 2024 seasonal influenza vaccines

Vaccine safety in Australia AusVaxSafety summary report now available

What to expect in the days after your XBB.1.5 COVID-19 vaccine

Shingrix® vaccine safety data now available

Subscribe to our newsletter for immunisation professionals

Subscribe to our newsletter for immunisation professionals